Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- Gut. 2024 Feb 23;73(3):533-540. doi: 10.1136/gutjnl-2023-331003.
- 1. Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea.
- 2. Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, South Korea.
- 3. Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, South Korea.
- 4. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
- 5. Yonsei Liver Center, Severance Hospital, Seoul, South Korea.
- 6. Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea [email protected] [email protected].
- 7. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea [email protected] [email protected].
Objective: We explored clinical implications of the new definition of metabolic dysfunction-associated steatotic Liver Disease (MASLD) by assessing its prevalence and associated Cardiovascular Disease (CVD) risk.
Design: From nationwide health screening data, we identified 9 775 066 adults aged 20-79 who underwent health examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) MASLD with other combined aetiology (the three collectively referred to as MASLD/related steatotic Liver Disease (SLD)); and (4) no MASLD/related SLD. SLD was determined by fatty liver index ≥30. The primary outcome was CVD event, defined as a composite of Myocardial Infarction, ischaemic stroke, Heart Failure or cardiovascular death.
Results: The prevalence of MASLD, MetALD and MASLD with other combined aetiology was 27.5%, 4.4% and 1.5%, respectively. A total of 8 808 494 participants without prior CVD were followed up for a median of 12.3 years, during which 272 863 CVD events occurred. The cumulative incidence and multivariable-adjusted risk of CVD were higher in participants with MASLD/related SLD than in those without (HR 1.38 (95% CI 1.37 to 1.39)). Multivariable-adjusted HR (95% CI) of CVD events was 1.39 (1.38 to 1.40) for MASLD, 1.28 (1.26 to 1.30) for MetALD and 1.30 (1.26 to 1.34) for MASLD with other combined aetiology compared to the absence of any of these conditions. CVD risk was also higher in participants with metabolic dysfunction-associated Fatty Liver Disease or non-alcoholic Fatty Liver Disease than in those without the respective condition.
Conclusion: Over one-third of Korean adults have MASLD/related SLD and bear a high CVD risk.